Anemia Management in Chronic Kidney Disease
Initiation of Treatment
- The American Society of Nephrology recommends initiating erythropoiesis-stimulating agent (ESA) treatment when hemoglobin levels are below 10 g/dL in non-dialyzed patients and between 9-10 g/dL in dialyzed patients, after correcting iron deficiencies and treating other reversible causes of anemia 1, 2, 3
- The decision to initiate ESA treatment should consider the rate of hemoglobin decline, previous response to iron therapy, risk of transfusion, and presence of symptoms attributable to anemia 1, 2
- ESA treatment should not be initiated if hemoglobin levels are ≥ 10 g/dL 1, 3
Pre-Treatment Steps
- Iron deficiency should be treated before initiating ESA therapy, aiming for a serum ferritin level > 100 μg/L and a transferrin saturation > 20% 4, 5
- Other reversible causes of anemia, such as nutritional deficiencies and chronic inflammatory states, should be evaluated and treated 1, 2
Therapeutic Targets
- The target hemoglobin level is 11-12 g/dL, with an acceptable range of 10-12 g/dL 4, 6, 7
- Hemoglobin levels should not be maintained above 11.5 g/dL, and intentionally targeting levels above 13 g/dL should be avoided due to increased cardiovascular risk 1, 2, 6
Contraindications and Precautions
- ESA treatment should be used with caution in patients with active malignancy, history of stroke, or chronic cardiovascular disease 1, 2, 7, 8
- Excessive correction of anemia (hemoglobin > 13 g/dL) may increase the risk of cardiovascular events, stroke, and hypertension 1, 2, 6, 7